Initial interim 52-week results from Phase 2b Population Extension cohort of PRISM clinical trial to be presented by Dante Pieramici, M.D., a Principal Investigator in PRISM, at Angiogenesis, Exudation, and Degeneration 2025 on Saturday, February 8, 2025 at 2:20 p.m. ETCompany to host webcast on Monday, February 10, 2025 at 8:00 a.m. ET to discuss the 4D-150 interim data including recently diagnosed subgroup, which most resembles the Phase 3 4FRONT-1 and -2 patient populations EMERYVILLE, Calif., Jan. 29, 2 ...

NEW YORK, Jan. 29, 2025 (GLOBE NEWSWIRE) -- Fiverr International Ltd. (NYSE: FVRR), the company that is changing how the world works together, today announced it will release fourth quarter and full year financial results for the period ended December 31, 2024, before the market opens on Wednesday, February 19, 2025. On that day management will hold a conference call and webcast at 8:00 a.m. ET to discuss the Company’s business and financial results. Prior to its conference call, Fiverr will issue a press r ...

Company recognized for strategic integration of AI technologies, comprehensive partner ecosystem, and exceptional client flexibility and scalability in B2B sales servicesNEWARK, Calif., Jan. 29, 2025 (GLOBE NEWSWIRE) -- Concentrix Corporation (NASDAQ: CNXC), a global technology and services leader, today announced it has been recognized as the Highest Leader in Everest Group’s first-ever business-to-business (B2B) Sales Services PEAK Matrix® Assessment. Among 15 leading service providers evaluated, Concentr ...

NAARDEN, The Netherlands and MIAMI, Jan. 29, 2025 (GLOBE NEWSWIRE) -- NewAmsterdam Pharma Company N.V. (Nasdaq: NAMS or “NewAmsterdam” or the “Company”), a late-stage, clinical biopharmaceutical company developing oral, non-statin medicines for patients at risk of cardiovascular disease (“CVD”) with elevated low-density lipoprotein cholesterol (“LDL-C”), for whom existing therapies are not sufficiently effective or well-tolerated, today announced that Ian Somaiya, Chief Financial Officer of NewAmsterdam Pha ...

LONDON and NEW YORK, Jan. 29, 2025 (GLOBE NEWSWIRE) -- OKYO Pharma Limited (NASDAQ: OKYO), a clinical-stage biopharmaceutical company developing innovative therapies for the treatment of neuropathic corneal pain (NCP), a severe ocular condition without an FDA approved therapy, and for inflammatory dry eye disease (DED), a multi-billion-dollar market, today announces a clinical update and its interim results for the six months ended 30 September 2024. Clinical Updates: OK-101 Neuropathic Corneal Pain (NCP) T ...

San Diego, Calif., Jan. 29, 2025 (GLOBE NEWSWIRE) -- California BanCorp (“us,” “we,” “our,” or the “Company”) (NASDAQ: BCAL), the holding company for California Bank of Commerce, N.A. (the “Bank”) announces its consolidated financial results for the fourth quarter and full year of 2024. The Company reported net income of $16.8 million, or $0.51 per diluted share, for the fourth quarter of 2024, compared to a net loss of $16.5 million, or $0.59 per diluted share for the third quarter of 2024, and net income ...

Company Overview - GCM Grosvenor is a global alternative asset management solutions provider with approximately $80 billion in assets under management [3] - The firm manages assets across private equity, infrastructure, real estate, credit, and absolute return investment strategies [3] - GCM Grosvenor has specialized in alternatives for more than 50 years and leverages its cross-asset class and flexible investment platform to deliver value for clients [3] - The company employs approximately 550 professionals and serves a global client base of institutional and individual investors [3] - GCM Grosvenor is headquartered in Chicago with offices in New York, Toronto, London, Frankfurt, Tokyo, Hong Kong, Seoul, and Sydney [3] Upcoming Event - GCM Grosvenor will present at the Bank of America Securities Financial Services Conference on Wednesday, February 12, 2025, at 2:40 p.m. ET [1] - A live audio webcast of the presentation will be available on GCM Grosvenor's public shareholders website and the event website [2] - A replay of the webcast will be available within 24 hours after the conclusion of the live event [2]

DELAWARE, Ohio, Jan. 29, 2025 (GLOBE NEWSWIRE) -- Greif (NYSE: GEF, GEF.B), a global leader in industrial packaging products and services, announced today it will permanently cease production on the Number 1 Paperboard Machine (A1) in Austell, GA and permanently close the containerboard and uncoated recycled paperboard (URB) mill in Fitchburg, MA. “Decisions like these are extremely difficult because of the impact it has on our colleagues and their families, as well as the larger community,” said President ...

Clinical Development and Presentations - The company will present three posters for its lead therapeutic candidate, efzofitimod, at the American Thoracic Society (ATS) 2025 International Conference [1] - The posters include details on the EFZO-FIT trial design, real-world treatment patterns, and the incidence, prevalence, and mortality of pulmonary sarcoidosis in the US [2] - The EFZO-FIT trial is the largest placebo-controlled trial in pulmonary sarcoidosis, with topline data expected in Q3 2025 [1][2] About Efzofitimod - Efzofitimod is a first-in-class biologic immunomodulator in clinical development for the treatment of interstitial lung disease (ILD) [3] - It selectively modulates activated myeloid cells through neuropilin-2 to resolve inflammation without immune suppression and potentially prevent fibrosis progression [3] - The company is investigating efzofitimod in the global Phase 3 EFZO-FIT study for pulmonary sarcoidosis and the Phase 2 EFZO-CONNECT study for systemic sclerosis-related ILD [3] About aTyr - aTyr is a clinical-stage biotechnology company focused on translating tRNA synthetase biology into new therapies for fibrosis and inflammation [4] - The company's discovery platform leverages a proprietary library of domains derived from all 20 tRNA synthetases to uncover novel signaling pathways [4] - Efzofitimod is the lead therapeutic candidate, targeting immune-mediated disorders that cause inflammation and progressive fibrosis in the lungs [4]

PHILADELPHIA, Jan. 29, 2025 (GLOBE NEWSWIRE) -- Enviri Corporation (NYSE: NVRI) today announced that it will issue its fourth quarter and full year 2024 earnings results on Thursday, February 20, 2025, prior to NYSE market open. The Company will also host its quarterly conference call and webcast that morning beginning at 9:00 a.m. ET. Those who wish to listen to the conference call webcast should visit the Investor Relations section of the Company’s website at www.enviri.com. The live call also can be acce ...